QCOR Releases Update on Acthar Gel Prescriptions and Shipments, Sending Shares Higher

After publishing an update on on the company’s lead product, H.P. Acthar Gel, shares of Questcor Pharmaceuticals (NASDAQ:QCOR) were up 6% in early trading on Friday. The update, filed in an 8-k, shows significant prescription growth of the gel as well as an increase in vial shipments. H.P. Acthar Gel is an anti-inflammatory for patients with Multiple Sclerosis, Nephrotic Syndrome, Infantile Spasms, and its smallest market, Dermatomyositis/Polymyositis. Vial shipments increased by 33% from July to August, and have been growing steadily q-to-q since 2010.

PropThink reported Tuesday on the impact that Medicaid rebates have had on Acthar revenues, which are so high in some cases (100%) that the company makes no money on many prescriptions. But the Centers for Medicare and Medicaid (CMS) recently informed QCOR that Acthar Gel is eligible for a substantial rebate reduction, possibly to 23%, which will allow much higher profitability. Revenue is expected to grow significantly with the lowered rebates as Medicaid patients make up 50% of prescriptions in some Acthar Gel indications. Adding fuel to the fire on Friday is a large 42% short interest in QCOR that is helping to squeeze shares even higher in the morning. Strength should continue throughout the day.

PropThink’s previous QCOR coverage is available here.

Additional disclosure: PropThink is a team of editors, analysts, and writers. Use of PropThink's research is at your own risk. You should do your own research and due diligence before making any investment decision with respect to securities covered herein.You should assume that as of the publication date of any report or letter, PropThink, LLC and persons or entities with whom it has relation ships (collectively referred to as "PropThink") has a position in all stocks (and/or options of the stock) covered herein that is consistent with the position set forth in our research report. Following publication of any report or letter, PropThink intends to continue transacting in the securities covered herein, and we may be long, short, or neutral at any time hereafter regardless of our initial recommendation. To the best of our knowledge and belief, all information contained herein is accurate and reliable, and has been obtained from public sources we believe to be accurate and reliable, and not from company insiders or persons who have a relationship with company insiders. Our full disclaimer is available at this link.